Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Diuretics in the therapy of hypertension

Journal of Human Hypertension volume 16, pages S78–S83 (2002)Cite this article

Abstract

Antihypertensive monopharmacotherapy with diuretics renders blood pressure (BP) values under control in a large percentage of patients suffering from essential hypertension, and it reduces cardiovascular morbidity and mortality. Diuretics are effective in adult and elderly hypertensive subjects, independently of their race. Treatments with classic (high) doses of antihypertensive diuretics, such as 25 mg hydrochlorothiazide once daily, raise the activity of the RAA system, decrease plasma potassium and magnesium concentrations, and cause untoward changes in carbohydrate metabolism and in the plasma lipid profile. These changes appear to limit the positive response of cardiovascular prognosis to antihypertensive therapy with classic doses of diuretics. Lower doses of diuretics reduce high BP to the sought extent in many patients, and they do not elicit or cause only mild unfavourable neuroendocrine and metabolic changes. When a low dose of an antihypertensive diuretic substance is used as monopharmacotherapy, it may take 12–14 weeks after the initiation of treatment for BP to attain final stable values. The following low-dose oral formulations of diuretics constitute effective once-daily monopharmacotherapies for mild-to-moderate uncomplicated essential hypertension: bendrofluazide 1.25 mg, chlorthalidone 12.5 and 15 mg, cicletanine 50 mg, cyclopenthiazide 0.125 mg, HCTZ 12.5 mg, and torasemide 2.5 and 5 mg. These formulations are safer than classically used high-dose formulations such as hydrochlorothiazide 25 and 50 mg.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Psaty BM et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis JAMA 1997 277: 739–745

    Article  CAS  Google Scholar 

  2. Messerli FH, Grossman E, Goldbourt U . Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review JAMA 1998 279: 1903–1907

    Article  CAS  Google Scholar 

  3. Siscovic DS et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest N Engl J Med 1994 330: 1852–1857

    Article  Google Scholar 

  4. Grobbee DE, Hoes AW . Non-potassium-sparing diuretics and risk of sudden cardiac death J Hypertens 1995 13: 1539–1545

    CAS  PubMed  Google Scholar 

  5. Reyes AJ, Taylor SH . Diuretics in cardiovascular medicine: the new clinicopharmacological bases that matter Cardiovasc Drugs Ther 1999 13: 371–398

    Article  CAS  Google Scholar 

  6. Leary WP, Reyes AJ, van der Byl K . Urinary excretory responses to the alpha-2 sympathetic agonist rilmenilacute;dine, to hydrochlorothiazide and to their combination in healthy subjects In: Puschett JB, Greenberg A (eds) Diuretics IV: Chemistry, Pharmacology and Clinical Applications Excerpta Medica: Amsterdam 1993 pp 387–390

    Google Scholar 

  7. Reyes AJ . Antihypertensive monopharmacotherapy with very-low-dose, low-dose, and high-dose formulations of diuretics: efficacy and safety In: Reyes AJ, Maranho MFC (eds) Cardiovascular Pharmacotherapy. Proceedings of the 9th International Congress on Cardiovascular Pharmacotherapy Monduzzi:Bologna 2000 pp 229–234

    Google Scholar 

  8. Reyes AJ, Leary WP . Clinicopharmacological reappraisal of the potency of diuretics Cardiovasc Drugs Ther 1993 7: 23–28

    Article  Google Scholar 

  9. Franse LV et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program Hypertension 2000 35: 1025–1030

    Article  CAS  Google Scholar 

  10. Reyes AJ, Leary WP, van der Byl K . Renal excretory responses to single and repeated administration of loop and of distal tubular diuretics at various doses in healthy man Prog Pharmacol Clin Pharmacol 1992 9: 219–262

    CAS  Google Scholar 

  11. Reyes AJ . Diuretics and magnesium: clinical pharmacology in healthy subjects. In: Theophanides T, Anastassopoulou J (eds) Magnesium: Current Status and New Developments Kluwer: Dordrecht 1997 199–208

    Chapter  Google Scholar 

  12. Reyes AJ, Leary WP, Espinas RD . Once-daily treatments with usual doses of the loop diuretic torasemide do not reduce serum zinc concentration Eur Heart J 1999 20 (Abstract Suppl): 551 (abstract)

    Google Scholar 

  13. Carlsen JE, Kober L, Torp-Pedersen C, Johansen C . Relations between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects BMJ 1990 300: 975–978

    Article  CAS  Google Scholar 

  14. Johnston GD, Girvin B, McGavock H . A comparison of conventional dose versus low dose and alternate day dosing of bendrofluazide in terms of blood pressure lowering andpatient compliance J Hypertens 1997 15: 1549–1550

    Article  Google Scholar 

  15. Wiggam MI et al. Low dose bendrofluazide (1.25 mg) effectively lowers blood pressure over 24 h. Results of a randomized, double-blind, placebo-controlled crossover study Am J Hypertens 1999 12: 528–531

    Article  CAS  Google Scholar 

  16. Korduner Y, Käbin L, Hagbarth G . Low-dose chlorthalidone treatment in previously untreated hypertension Curr Ther Res 1981 29: 208–215

    Google Scholar 

  17. Vardan S et al. Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study JAMA 1987 258: 484–484

    Article  CAS  Google Scholar 

  18. McVeigh G, Galloway D, Johnston D . The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide BMJ 1988 297: 95–98

    Article  CAS  Google Scholar 

  19. Johnston GD et al. Low-dose cyclopenthiazide in the treatment of hypertension: a one-year community-based study Q J Med 1991 78: 135–143

    CAS  PubMed  Google Scholar 

  20. Beermann B, Groschinsky-Grind M . Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug Eur J Clin Pharmacol 1978 13: 195–201

    Article  CAS  Google Scholar 

  21. Scholze J et al for the East Germany Collaborative Trial Group. Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design J Hypertens 1993 11 (Suppl 2): S25–S33

    Google Scholar 

  22. Schoenberger JA for the Losartan Research Group. Losartan with hydrochlorothiazide in the treatment of hypertension J Hypertens 1995 13 (Suppl 1): S43–S47

    Google Scholar 

  23. MacKay JH et al. Losartan and low-dose hydrochlorothiazide inpatients with essential hypertension Arch Intern Med 1996 156: 278–285

    Article  CAS  Google Scholar 

  24. Philipp T, Letzel H, Arens H-J . Dose-finding study of candesartan cilexetil plus hydrochlorothiazide inpatients with mild to moderate hypertension J Hum Hypertens 1997 11 (Suppl 2): S67–S68

    Google Scholar 

  25. Kochar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension Am J Hypertens 1999 12: 797–805

    Article  CAS  Google Scholar 

  26. Toth PD . Clinical efficacy and safety of indapamide 1.25 mg in mild to moderate hypertension Am J Hypertens 1994 7: 37A (abstract)

    Google Scholar 

  27. Fiddes R et al. Evaluation of indapamide 1.25 mg once daily in elderlypatients with mild to moderate hypertension J Hum Hypertens 1997 11: 239–244

    Article  CAS  Google Scholar 

  28. Harper R et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension BMJ 1994 309: 226–230

    Article  CAS  Google Scholar 

  29. Harper R et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensivepatients with NIDDM Diabetologia 1995 38: 853–859

    Article  CAS  Google Scholar 

  30. Girvin B, Johnston GD . A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensivepatients J Hypertens 1998 16: 1049–1054

    Article  CAS  Google Scholar 

  31. McVeigh GE et al. Low and conventional dose cyclopenthiazide on glucose and lipid metabolism in mild hypertension Br J Clin Pharmacol 1989 27: 523–526

    Article  CAS  Google Scholar 

  32. McVeigh GE et al. A comparison of the haemodynamic and hormonal effects of low and conventional dose cyclopenthiazide in normal volunteers Eur J Clin Pharmacol 1990 38: 351–357

    Article  CAS  Google Scholar 

  33. Reyes AJ et al. Hydrochlorothiazide versus a non-diuretic dose of torasemide as once-daily antihypertensive monopharmacotherapy in elderlypatients. A randomized and double-blind study Prog Pharmacol Clin Pharmacol 1990 8/1: 183–209

    Google Scholar 

  34. Reyes AJ . Formal comparison of the antihypertensive effects of torasemide and other diuretics by the Montevideo Mathematical Model Arzneimittelforschung 1988 38: 194–199

    CAS  PubMed  Google Scholar 

  35. Bölke T, Achhammer l, Meyer-Sabellek WA, Streitberg P . Tages- und Nachtrhythmik ambulanter 24-h-Blutdruckwerte von älteren essentiellen Hypertonikern bei Therapie mit verschiedenen Antihypertonika Hochdruck 1990 10: 40 (abstract)

    Google Scholar 

  36. Fodor G, Guinot P . Review of 3 studies to determine the efficacy and tolerance of cicletanine in the short & long term treatment of essential hypertension Drugs Exp Clin Res 1988 14: 195–204

    CAS  PubMed  Google Scholar 

  37. Tarrade T et al. Efficacité antihypertensive et tolérance du cicletanine. Résultats obtenues en monothérapie sur une large population Arch Mal Coeur 1989 82: 91–97

    PubMed  Google Scholar 

  38. Baumgart P, Walger P v . Eiff M, Achhammer I. Long term efficacy and tolerance of torasemide in hypertension Prog Pharmacol Clin Pharmacol 1990 8/1: 169–181

    Google Scholar 

  39. Dupont AG, Schoors D, Six RO, Vanhaelst L . Antihypertensive efficacy of low dose torasemide in essential hypertension J Hum Hypertens 1988 2: 265–268

    CAS  PubMed  Google Scholar 

  40. Achhammer I, Eberhard R . Comparison of serum potassium levels during long-term treatment of hypertensivepatients with 2.5 mg torasemide/day or 50 mg triamterene/25 mg hydrochlorothiazide/day Prog Pharmacol Clin Pharmacol 1990 8/1: 211–220

    Google Scholar 

  41. Bölke T, Achhammer I, Meyer-Sabellek WA . Blutdrucksenkung und metabolische Veranderungen bei essentiellen Hypertonikern nach Langzeitgabe unterschiedlicher Diuretika Hochdruck 1990 10: 40–41 (abstract)

    Google Scholar 

  42. Achhammer I, Metz P . Low dose loop diuretics in essential hypertension: experience with torasemide Drugs 1991 41 (Suppl 3): 80–91

    Article  Google Scholar 

  43. Reyes AJ . Renal excretory profiles of loop diuretics — consequences for therapeutic application J Cardiovasc Pharmacol 1993 22 (Suppl 3): S11–S23

    Article  Google Scholar 

  44. Reyes AJ, Leary WP, van der Byl K . Lack of effect of cicletanine on uric acid Am J Hypertens 2000 13: 114A (abstract)

    Google Scholar 

  45. Asmar R et al. Bénéfice thérapeutique d'une faible dose d'indapamide: résultats d'une étude européenne contrôlée en double-aveugle contre placebo Arch Mal Coeur 1995 88: 1083–1087

    CAS  PubMed  Google Scholar 

  46. Ambrosioni E et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group J Hypertens 1998 6: 1677–1684

    Article  Google Scholar 

  47. Grossman E, Messerli FH, Goldbourt U . High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000 160: 2447–2452

    Article  CAS  Google Scholar 

  48. Lindholm LH et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabeticpatients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group J Hypertens 2000 18: 1671–1675

    Article  CAS  Google Scholar 

  49. Komers R, Komersova K . Therapeutic potential of ACE inhibitors for the treatment of hypertension in type 2 diabetes Expert Opin Investig Drugs 2000 9: 2601–2617

    Article  CAS  Google Scholar 

  50. Cogan E, Abromow M . Diuretic-induced hyponatraemia in elderly hypertensive women Lancet 1983 2: 1249

    Article  CAS  Google Scholar 

  51. Castaigne A et al. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderlypatients with mild to moderate hypertension Clin Exp Hypertens 1999 21: 1097–1110

    Article  CAS  Google Scholar 

  52. Chalmers J, Castaigne A, Morgan T, Chastang C . Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensivepatients J Hypertens 2000 18: 327–337

    Article  CAS  Google Scholar 

  53. Mallion JM, Chastang C, Unger P . Efficacy and safety of a fixed low-dose perindopril/indapamide combination in essential hypertension. A randomised controlled study Clin Exp Hypertens 2000 22: 23–32

    Article  CAS  Google Scholar 

  54. Fernandes M et al. The antihypertensive effect of indapamide in low doses Curr Med Res Opin 1977 5 (Suppl 1): 60–63

    Article  Google Scholar 

  55. Hashida JG . A double-blind multicentre study of indapamide in the treatment of essential hypertension Curr Med Res Opin 1977 5 (Suppl 1): 116–123

    Article  Google Scholar 

  56. Luccioni R, Frances Y, Gass R, Gilgenkrantz JM . Evaluation of the dose-effect relationship of perindopril in the treatment of hypertension Clin Exp Hypertens A 1989 11 (Suppl 2): 521–534

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Cardiovascular Theory, Montevideo, Uruguay

    A J Reyes

Authors
  1. A J Reyes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A J Reyes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reyes, A. Diuretics in the therapy of hypertension. J Hum Hypertens 16 (Suppl 1), S78–S83 (2002). https://doi.org/10.1038/sj.jhh.1001349

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001349

Keywords

This article is cited by

Search

Advanced search

Quick links